Antidepressant use during pregnancy: Current controversies and treatment strategies

Jennifer Payne, Samantha Meltzer-Brody

Research output: Contribution to journalArticle

Abstract

The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.

Original languageEnglish (US)
Pages (from-to)469-482
Number of pages14
JournalClinical Obstetrics and Gynecology
Volume52
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Antidepressive Agents
Mothers
Pregnancy
Depression
Fetus
Neonatal Abstinence Syndrome
Premature Birth
Therapeutics
Newborn Infant
Safety

Keywords

  • Antidepressants
  • Depression
  • Neonatal withdrawal syndrome
  • PPHN
  • Pregnancy
  • Safety

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Antidepressant use during pregnancy : Current controversies and treatment strategies. / Payne, Jennifer; Meltzer-Brody, Samantha.

In: Clinical Obstetrics and Gynecology, Vol. 52, No. 3, 09.2009, p. 469-482.

Research output: Contribution to journalArticle

@article{25a19477840e4eb68137ffb0265185e0,
title = "Antidepressant use during pregnancy: Current controversies and treatment strategies",
abstract = "The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.",
keywords = "Antidepressants, Depression, Neonatal withdrawal syndrome, PPHN, Pregnancy, Safety",
author = "Jennifer Payne and Samantha Meltzer-Brody",
year = "2009",
month = "9",
doi = "10.1097/GRF.0b013e3181b52e20",
language = "English (US)",
volume = "52",
pages = "469--482",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Antidepressant use during pregnancy

T2 - Current controversies and treatment strategies

AU - Payne, Jennifer

AU - Meltzer-Brody, Samantha

PY - 2009/9

Y1 - 2009/9

N2 - The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.

AB - The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.

KW - Antidepressants

KW - Depression

KW - Neonatal withdrawal syndrome

KW - PPHN

KW - Pregnancy

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=69449092488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449092488&partnerID=8YFLogxK

U2 - 10.1097/GRF.0b013e3181b52e20

DO - 10.1097/GRF.0b013e3181b52e20

M3 - Article

C2 - 19661762

AN - SCOPUS:69449092488

VL - 52

SP - 469

EP - 482

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 3

ER -